• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018 Product Image

Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018

  • ID: 2374280
  • January 2013
  • Region: Global
  • 112 Pages
  • Transparency Market Research

FEATURED COMPANIES

  • ABBOTT LABORATORIES
  • ASTELLAS PHARMA INC.
  • BRISTOL-MYERS SQUIBB
  • GILEAD SCIENCES
  • GLAXOSMITHKLINE PLC
  • NOVARTIS AG
  • MORE

This report covers the performance of the various drugs class segment used in liver disease therapeutics in terms of their revenue. The global market for liver diseases therapeutics is classified into seven drug class segments namely, anti-viral drugs, vaccines, immunosuppressants, immunoglobulins, targeted therapy, corticosteroids and chemotherapy with their estimated and forecasted market size from 2012 to 2018, along with their compound annual growth rate.

This report also covers an in-depth competitive analysis for the market, taking into consideration some of the major market players. The market players considered are: Abbott Laboratories, Astellas Pharma Inc, Gilead Science Inc., Merck & Co., Bristol-Myers Squibb, Novartis, Pfizer and Roche. A detailed analysis of their business strategies, company overview, financial overview, product portfolio and recent developments is also provided in the report.

We have used secondary research for deriving our market numbers for each segment of the research report and further validated our analysis with C-level executives of major companies operating in liver diseases therapeutics market through the means of primary research to finally come up with our results. This research is specially designed to estimate and analyze the performance of liver diseases therapeutics in a global scenario. This research provides in-depth analysis of liver diseases therapeutics market sales, trend analysis by segments.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ABBOTT LABORATORIES
  • ASTELLAS PHARMA INC.
  • BRISTOL-MYERS SQUIBB
  • GILEAD SCIENCES
  • GLAXOSMITHKLINE PLC
  • NOVARTIS AG
  • MORE

CHAPTER 1 PREFACE
1.1 REPORT DESCRIPTION
1.2 RESEARCH METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SIZE
3.3 COMPARATIVE ANALYSIS OF GLOBAL LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS, 2011 & 2018
3.4 LIVER DISEASES THERAPEUTICS MARKET DYNAMICS
3.4.1 DRIVERS
3.4.1.1 Aging population inducing chronic liver diseases such as hepatitis and liver cancer
3.4.1.2 Increasing global prevalence of liver diseases
3.4.1.3 High unmet needs exist in the liver cancer therapeutics
3.4.1.4 Increased vaccination in emerging economies
3.4.2 LIVER DISEASE THERAPEUTICS MARKET DRIVERS IMPACT ANALYSIS
3.4.3 RESTRAINTS
3.4.3.1 Side-effects and risks
3.4.3.2 FDA approvals and other government regulations
3.4.3.3 Availability of alternate treatment procedures
3.4.4 LIVER DISEASE THERAPEUTICS MARKET RESTRAINTS IMPACT ANALYSIS
3.4.5 OPPORTUNITIES
3.4.5.1 Strong pipeline drugs
3.4.5.2 Emerging economies in Asia, Latin America and Eastern European countries
3.4.5.3 Consolidation opportunities in the healthcare industry
3.5 PORTER’S FIVE FORCES ANALYSIS FOR LIVER DISEASES THERAPEUTICS MARKET
3.5.1 BARGAINING POWER OF SUPPLIERS
3.5.2 BARGAINING POWER OF BUYERS
3.5.3 THREAT OF NEW ENTRANTS
3.5.4 THREAT OF SUBSTITUTES
3.5.5 COMPETITIVE RIVALRY

CHAPTER 4 LIVER DISEASES CLASSIFICATION AND THERAPY OPTIONS
4.1 ALCOHOL INDUCED LIVER DISEASE
4.1.1 OVERVIEW
4.1.2 EPIDEMIOLOGY
4.1.3 ETIOLOGY
4.1.4 SYMPTOMS
4.1.5 PATHOPHYSIOLOGY
4.1.6 TREATMENT PATTERN AND THERAPY OPTIONS
4.1.6.1 Anabolic Steroids
4.1.6.2 Alcohol Abuse Drugs
4.2 AUTOIMMUNE LIVER DISORDER
4.2.1 AUTOIMMUNE HEPATITIS (AIH)
4.2.1.1 OVERVIEW
4.2.1.2 EPIDEMIOLOGY
4.2.1.3 ETIOLOGY
4.2.1.4 SYMPTOMS
4.2.1.5 PATHOPHYSIOLOGY
4.2.1.6 TREATMENT PATTERN AND THERAPY OPTIONS
4.2.1.6.1 Antimetabolites
4.2.1.6.2 Corticosteroids
4.3 HEPATOCELLULAR CARCINOMA
4.3.1 OVERVIEW
4.3.2 EPIDEMIOLOGY
4.3.3 ETIOLOGY
4.3.4 SYMPTOMS
4.3.5 PATHOPHYSIOLOGY
4.3.6 TREATMENT PATTERN AND THERAPY OPTIONS
4.3.6.1 Chemotherapy
4.3.6.2 Targeted Therapy
4.4 NON-ALCOHOLIC FATTY LIVER DISEASE
4.4.1 OVERVIEW
4.4.2 EPIDEMIOLOGY
4.4.3 ETIOLOGY
4.4.4 SYMPTOMS
4.4.5 PATHOPHYSIOLOGY
4.4.6 TREATMENT PATTERN AND THERAPY OPTIONS
4.4.6.1 Gallstone solubilising drugs
4.5 VIRAL/HEPATITIS LIVER DISORDER
4.5.1 HEPATITIS A
4.5.1.1 OVERVIEW
4.5.1.2 EPIDEMIOLOGY
4.5.1.3 ETIOLOGY
4.5.1.4 SYMPTOMS
4.5.1.5 PATHOPHYSIOLOGY
4.5.1.6 TREATMENT PATTERN AND THERAPY OPTIONS
4.5.1.6.1 Vaccines
4.5.1.6.2 Immunoglobulins
4.5.2 HEPATITIS B
4.5.2.1 OVERVIEW
4.5.2.2 EPIDEMIOLOGY
4.5.2.3 ETIOLOGY
4.5.2.4 SYMPTOMS
4.5.2.5 PATHOPHYSIOLOGY
4.5.2.6 TREATMENT PATTERN AND THERAPY OPTIONS
4.5.2.6.1 Antiviral drugs
4.5.2.6.2 Immunoglobulins
4.5.2.6.3 Vaccines
4.5.3 HEPATITIS C
4.5.3.1 OVERVIEW
4.5.3.2 EPIDEMIOLOGY
4.5.3.3 ETIOLOGY
4.5.3.4 SYMPTOMS
4.5.3.5 PATHOPHYSIOLOGY
4.5.3.6 TREATMENT PATTERN AND THERAPY OPTIONS
4.5.3.6.1 Antiviral drugs
4.5.4 HEPATITIS D
4.5.4.1 OVERVIEW
4.5.4.2 EPIDEMIOLOGY
4.5.4.3 ETIOLOGY
4.5.4.4 SYMPTOMS
4.5.4.5 PATHOPHYSIOLOGY
4.5.4.6 TREATMENT PATTERN AND THERAPY OPTIONS
4.5.5 HEPATITIS E
4.5.5.1 OVERVIEW
4.5.5.2 EPIDEMIOLOGY
4.5.5.3 ETIOLOGY
4.5.5.4 SYMPTOMS
4.5.5.5 PATHOPHYSIOLOGY
4.5.5.6 TREATMENT PATTERN AND THERAPY OPTIONS

CHAPTER 5 LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS
5.1 IMMUNOSUPPRESSANTS
5.1.1 GLOBAL IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
5.2 CHEMOTHERAPY DRUGS
5.2.1 GLOBAL CHEMOTHERAPY DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
5.3 TARGETED THERAPY DRUGS
5.3.1 GLOBAL TARGETED THERAPY MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
5.4 VACCINES
5.4.1 GLOBAL VACCINES MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
5.5 ANTI-VIRAL DRUGS
5.5.1 GLOBAL ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
5.6 IMMUNOGLOBULINS
5.6.1 GLOBAL IMMUNOGLOBULINS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
5.7 CORTICOSTERIODS
5.7.1 GLOBAL CORTICOSTERIODS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)

CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 MARKET SHARE OF KEY PLAYERS IN LIVER DISEASES THERAPEUTICS MARKET BY DRUG CLASS
6.1.1 MARKET SHARE OF KEY PLAYERS FOR IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASES
6.1.2 MARKET SHARE OF KEY PLAYERS FOR VACCINES MARKET FOR LIVER DISEASES
6.1.3 MARKET SHARE OF KEY PLAYERS FOR ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASES
6.1.4 MARKET SHARE OF KEY PLAYERS FOR TARGETED THERAPY FOR LIVER DISEASES
6.1.5 NEW ENTRANTS (PHASE III)
6.1.6 COMPETITIVE STRATEGY BY KEY PLAYERS
6.1.6.1 Investments in R&D and clinical studies
6.1.6.2 Entering the emerging economies
6.1.6.3 Investing in different segments of the market
6.1.7 COMPETITIVE STRATEGY BY NEW ENTRANTS
6.1.8 AGREEMENTS AND COLLABORATIONS

CHAPTER 7 RECOMMENDATIONS
7.1 MARKET STRATEGY FOR SUCCESS
7.2 BARRIERS TO BE CONSIDERED

CHAPTER 8 COMPANY PROFILES
8.1 ABBOTT LABORATORIES
8.1.1 COMPANY OVERVIEW
8.1.2 FINANCIAL OVERVIEW
8.1.3 BUSINESS STRATEGIES
8.1.3.1 Significant R&D investments for new products development
8.1.3.2 Investing in emerging markets
8.1.3.3 Conducting clinical trials
8.1.4 PRODUCT PORTFOLIO
8.1.5 RECENT DEVELOPMENTS
8.2 ASTELLAS PHARMA INC.
8.2.1 COMPANY OVERVIEW
8.2.2 FINANCIAL OVERVIEW
8.2.3 BUSINESS STRATEGIES
8.2.3.1 Investing in emerging economies
8.2.3.2 Investing in research and development
8.2.4 PRODUCT PORTFOLIO
8.2.5 RECENT DEVELOPMENTS
8.3 BRISTOL-MYERS SQUIBB
8.3.1 COMPANY OVERVIEW
8.3.2 FINANCIAL OVERVIEW
8.3.3 BUSINESS STRATEGIES
8.3.3.1 Mergers, acquisitiosn and strategic development
8.3.3.2 Investing in research and development
8.3.4 PRODUCT PORTFOLIO
8.3.5 RECENT DEVELOPMENTS
8.4 GILEAD SCIENCES
8.4.1 COMPANY OVERVIEW
8.4.2 FINANCIAL OVERVIEW
8.4.3 BUSINESS STRATEGIES
8.4.3.1 Innovative new products
8.4.3.2 Investing in research and development
8.4.4 PRODUCT PORTFOLIO
8.4.5 RECENT DEVELOPMENTS
8.5 GLAXOSMITHKLINE PLC
8.5.1 COMPANY OVERVIEW
8.5.2 FINANCIAL OVERVIEW
8.5.3 BUSINESS STRATEGIES
8.5.3.1 Research and development investments
8.5.3.2 Delivering new products
8.5.4 PRODUCT PORTFOLIO
8.5.5 RECENT DEVELOPMENTS
8.6 F. HOFFMANN-LA ROCHE LTD
8.6.1 COMPANY OVERVIEW
8.6.2 FINANCIAL OVERVIEW
8.6.3 BUSINESS STRATEGIES
8.6.3.1 Strategic alliance initiative
8.6.3.2 Investing in research and development
8.6.4 PRODUCT PORTFOLIO
8.6.5 RECENT DEVELOPMENTS
8.7 MERCK & CO. INC
8.7.1 COMPANY OVERVIEW
8.7.2 FINANCIAL OVERVIEW
8.7.3 BUSINESS STRATEGIES
8.7.3.1 R&D initiatives
8.7.3.2 Strategic alliance
8.7.3.3 Corporate social responsibility and awareness
8.7.4 PRODUCT PORTFOLIO
8.7.5 RECENT DEVELOPMENTS
8.8 NOVARTIS AG
8.8.1 COMPANY OVERVIEW
8.8.2 FINANCIAL OVERVIEW
8.8.3 BUSINESS STRATEGIES
8.8.3.1 Strategic alliance
8.8.3.2 Investing in research and development
8.8.4 PRODUCT PORTFOLIO
8.8.5 RECENT DEVELOPMENTS
8.9 SANOFI S.A
8.9.1 COMPANY OVERVIEW
8.9.2 FINANCIAL OVERVIEW
8.9.3 BUSINESS STRATEGIES
8.9.3.1 Business Diversification
8.9.3.2 Research and development initiative
8.9.4 PRODUCT PORTFOLIO
8.9.5 RECENT DEVELOPMENTS
8.10 PFIZER INC.
8.10.1 COMPANY OVERVIEW
8.10.2 FINANCIAL OVERVIEW
8.10.3 BUSINESS STRATEGIES
8.10.3.1 Investing in research and development
8.10.4 PRODUCT PORTFOLIO
8.10.5 RECENT DEVELOPMENTS
8.11 TAKEDA PHARMACEUTICAL
8.11.1 COMPANY OVERVIEW
8.11.2 FINANCIAL OVERVIEW
8.11.3 BUSINESS STRATEGIES
8.11.3.1 Investing in emerging economies
8.11.3.2 Investing in research and development
8.11.4 PRODUCT PORTFOLIO
8.11.5 RECENT DEVELOPMENTS
8.12 VALEANT PHARMACEUTICALS
8.12.1 COMPANY OVERVIEW
8.12.2 FINANCIAL OVERVIEW
8.12.3 BUSINESS STRATEGIES
8.12.3.1 Strategic alliance
8.12.4 PRODUCT PORTFOLIO
8.12.5 RECENT DEVELOPMENTS
8.13 WATSON PHARMACEUTICALS, INC.
8.13.1 COMPANY OVERVIEW
8.13.2 FINANCIAL OVERVIEW
8.13.3 BUSINESS STRATEGIES
8.13.3.1 Investing in generic and biosimilar segments
8.13.3.2 Investing in research and development
8.13.4 PRODUCT PORTFOLIO
8.13.5 RECENT DEVELOPMENTS

LIST OF FIGURES

FIG. 1 GLOBAL LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS, 2011 (USD MILLION)
FIG. 2 LIVER DISEASES THERAPEUTICS MARKET SEGMENTATION
FIG. 3 COMPARATIVE MARKET SHARE ANALYSIS OF GLOBAL LIVER DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2011 & 2018
FIG. 4 PORTER’S FIVE FORCES ANALYSIS FOR THE LIVER DISEASES THERAPEUTICS MARKET
FIG. 5 PROGRESSION OF ALCOHOL INDUCED LIVER DISEASE IN HEAVY DRINKERS
FIG. 6 PROGRESSION OF HEPATOCELLULAR CANCER
FIG. 7 TWO-HIT CONCEPT OF NON-ALCOHOLIC FATTY LIVER DISEASE
FIG. 8 PATHOGENESIS OF HEPATITIS A VIRUS
FIG. 9 GLOBAL IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
FIG. 10 GLOBAL CHEMOTHERAPY MARKET FOR LIVER DISEASE THERAPEUTICS , 2010 – 2018 (USD MILLION)
FIG. 11 GLOBAL TARGETED THERAPY MARKET FOR LIVER DISEASE THERAPEUTICS, 2010– 2018 (USD MILLION)
FIG. 12 GLOBAL ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASES THERAPEUTICS, 2010 – 2018 (USD MILLION)
FIG. 13 GLOBAL IMMUNOGLOBULINS MARKET FOR LIVER DISEASES THERAPEUTICS, 2010 – 2018 (USD MILLION)
FIG. 14 GLOBAL CORTICOSTERIODS MARKET FOR LIVER DISEASES THERAPEUTICS, 2010 – 2018 (USD MILLION)
FIG. 15 MARKET SHARE OF KEY PLAYERS FOR IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASES, 2011 (%)
FIG. 16 MARKET SHARE OF KEY PLAYERS FOR VACCINES MARKET FOR LIVER DISEASES, 2011 (%)
FIG. 17 MARKET SHARE OF KEY PLAYERS FOR ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASES, 2011 (%)
FIG. 18 ABBOTT LABORATORIES NET SALES, 2008-2011 (USD MILLION)
FIG. 19 ASTELLAS PHARMA INC. ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 20 BRISTOL-MYERS SQUIBB ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 21 GILEAD SCIENCE ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 22 GLAXO SMITHKLINE ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 23 F. HOFFMANN-LA ROCHE LTD. ANNUAL SALES, 2007-2011 (USD MILLION)
FIG. 24 MERCK & CO, INC. ANNUAL REVENUE, 2007 – 2011 (USD MILLION)
FIG. 25 NOVARTIS AG. ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 26 SANOFI SA. ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 27 PFIZER INC. ANNUAL REVENUE, 2009-2011 (USD MILLION)
FIG. 28 TAKEDA INC. ANNUAL REVENUE, 2007-2011 (USD MILLION)
FIG. 29 VALEANT PHARMACEUTICAL ANNUAL REVENUE, 2008-2011 (USD MILLION)
FIG. 30 WATSON PHARMACEUTICALS INC., 2007-2011 (USD MILLION)

LIST OF TABLES

TABLE 1 GLOBAL LIVER DISEASES THERAPEUTICS MARKET: SNAPSHOT
TABLE 2 GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2010 - 2018
TABLE 3 IMPACT ANALYSIS OF DRIVERS
TABLE 4 IMPACT ANALYSIS OF RESTRAINTS
TABLE 5 PIPELINE DRUGS FOR LIVER DISEASES THERAPEUTICS (PHASE III)
TABLE 6 RECENT AGREEMENT AND COLLABORATION OF KEY PLAYERS

Note: Product cover images may vary from those shown

- ABBOTT LABORATORIES
- ASTELLAS PHARMA INC.
- BRISTOL-MYERS SQUIBB
- GILEAD SCIENCES
- GLAXOSMITHKLINE PLC
- F. HOFFMANN-LA ROCHE LTDMERCK & CO. INC
- NOVARTIS AG
- SANOFI S.A
- PFIZER INC.
- TAKEDA PHARMACEUTICAL
- VALEANT PHARMACEUTICALS
- WATSON PHARMACEUTICALS, INC.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos